ReviewFrontiers in psychiatry2017
Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.
Review in Frontiers in psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of ayahuasca in preclinical studies with animals: a systematic review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Pooled it
- Phase I Metabolism of Novel Phencyclidine Derivative 3-Cl-PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post-Mortem Case.Drug testing and analysis · 2026Article
- Novel Synthetic Opioids (NSOs) and Their Evolving Crisis: Utilising NPSPharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluating the drug interactions in kratom usage: clinical application.Expert opinion on drug metabolism & toxicology · 2025Review
- A Systematic Review on the Therapeutic Effects of Ayahuasca.Plants (Basel, Switzerland) · 2023Review
- Substance use and substance use disorders in Africa: An epidemiological approach to the review of existing literature.World journal of psychiatry · 2022Review
- Mitragynine improves cognitive performance in morphine-withdrawn rats.Psychopharmacology · 2022Article
- The Therapeutic Potential of Psilocybin.Molecules (Basel, Switzerland) · 2021Review
- Kratom use for depression/anxiety self-management: challenges during the COVID-19 pandemic - A case report.Heliyon · 2021Article
- Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples.Molecules (Basel, Switzerland) · 2021Review
- "Hot" and "Cold" Cognition in Users of Club Drugs/Novel Psychoactive Substances.Frontiers in psychiatry · 2021Article
- Article
- Non-pharmacological factors that determine drug use and addiction.Neuroscience and biobehavioral reviews · 2020Review
- Novel Opioids: Systematic Web Crawling Within the e-Psychonauts' Scenario.Frontiers in neuroscience · 2020Article
- Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells.Scientific reports · 2019Article
- Methanolic extract of Mitragyna speciosa Korth leaf inhibits ethanol seeking behaviour in mice: involvement of antidopaminergic mechanism.Metabolic brain disease · 2019Article
- Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions.International journal of tryptophan research : IJTR · 2019Review
- Repeated Use of the Psychoactive Substance Ethylphenidate Impacts Neurochemistry and Reward Learning in Adolescent Male and Female Mice.Frontiers in neuroscience · 2019Article
- Abuse liability of mitragynine assessed with a self-administration procedure in rats.Psychopharmacology · 2018Article
- KRATOM AND THE OPIOID CRISIS.Innovations in clinical neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects. These drugs change the mental state and/or the behavioral performance of an individual and can be instrumentalized for various purposes. After the emergence of a novel psychoactive substance (NPS) and a period of experimental consumption, personal and medical benefits and harm potential of the NPS can be estimated on evidence base. This may lead to a legal classification of the NPS, which may range from limited medical use, controlled availability up to a complete ban of the drug form publically accepted use. With these measures, however, a drug does not disappear, but frequently continues to be used, which eventually allows an even better estimate of the drug's properties. Thus, only in rare cases, there is a final verdict that is no more questioned. Instead, the view on a drug can change from tolerable to harmful but may also involve the new establishment of a desired medical application to a previously harmful drug. Here, we provide a summary review on a number of NPS for which the neuropharmacological evaluation has made important progress in recent years. They include mitragynine ("Kratom"), synthetic cannabinoids (e.g., "Spice"), dimethyltryptamine and novel serotonergic hallucinogens, the cathinones mephedrone and methylone, ketamine and novel dissociative drugs, γ-hydroxybutyrate, γ-butyrolactone, and 1,4-butanediol. This review shows not only emerging harm potentials but also some potential medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.